It affects an estimated 20 million Americans and can cause short-term issues such as snoring, brain fog and daytime sleepiness but also severe long-term issues such as heart disease, dementia and early death
Recent EMA Pharmacovigilance Risk Assessment Committee reviews of GLP-1 receptor agonists found no causal association with suicidal thoughts or self-harm, though monitoring continues
With clinic locations in Bend, Oregon & Seattle, Washington, and telehealth services available across the Pacific Northwest, Flow Wellness makes access to expert care convenient and supportive wherever you are
Success depends on careful patient selection, proper protocol implementation, and ongoing monitoring
In our latest blog, Sahithi Vemula unpacks how a new era of prescription-to-OTC switches could make safe, effective medicines more accessible than ever: bit.ly/3WQxHH1 To view or add a comment, sign in This article contains my thoughts on an FDA plan to merge the medical product manufacturing inspectorate with the clinical trial compliance inspectorate (known as Bioresearch Monitoring or BIMO)
